520 Results

People

  1. Postow
    Postow
  2. Motzer
    Motzer
  3. Wolchok
    Wolchok
  4. Hellmann
    Hellmann
  5. Shoushtari
    Shoushtari
  6. Voss
    Voss
  7. Callahan
    Callahan
  8. Abou-Alfa
    Abou-Alfa
  9. Jones
    Jones
  10. Rosenberg
    Rosenberg

Groups

  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)
  7. GSK Faculty (83)
  8. Surgery (71)
  9. Gastrointestinal Oncology Service (65)
  10. Weinberg Fellows (61)
  1. "nivolumab"
Formats
  1. Journal Article (342)
  2. Review (93)
  3. Editorial (41)
  4. Meeting Abstract (18)
  5. Correspondence (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Book Section (4)
  9. Conference Paper (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)

More Groups

People
  1. Michael Postow (55)
  2. Robert Motzer (50)
  3. Jedd Wolchok (41)
  4. Margaret Callahan (28)
  5. Alexander Shoushtari (27)
  6. Matthew Hellmann (26)

More People

Years
  1. 2025 (35)
  2. 2024 (70)
  3. 2023 (75)
  4. 2022 (52)
  5. 2021 (45)
  6. 2020 (64)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (23)
  2. Journal of Clinical Oncology (22)
  3. Journal of Thoracic Oncology (21)
  4. Lancet Oncology (21)
  5. New England Journal of Medicine (19)
  6. Annals of Oncology (17)

More Publications

Publishers
  1. Elsevier Inc. (77)
  2. Elsevier Science, Inc. (50)
  3. Oxford University Press (35)
  4. Wiley Blackwell (32)
  5. Biomed Central Ltd (27)
  6. Nature Publishing Group (27)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)
    Meeting Abstract

    Lyman, J.; O'Reilly, E.; Wainberg, Z.; Fisher, G.; Wolff, R.; Ko, A.; O'Hara, M.; Singh, H.; Amaravadi, R.; Kimmelman, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Sequencing novel agents in frontline and second-line treatment of Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Quantitative diffusion-weighted imaging analyses to predict response to neoadjuvant immunotherapy in patients with locally advanced head and neck carcinoma
    Journal Article

    van der Hulst, H. J.; Vos, J. L.; Tissier, R.; Smit, L. A.; Martens, R. M.; Beets-Tan, R. G. H.; van den Brekel, M. W. M.; Zuur, C. L.; Castelijns, J. A.
    Cancers (2022)

    Fulltext@MSK | Save
  • Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features
    Correspondence

    Zibara, V.; Sen, F.; Scordo, M.; Falchi, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
    Journal Article

    Rini, B. I.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape
    Journal Article

    Golkaram, M.; Kuo, F.; Gupta, S.; Carlo, M. I.; Salmans, M. L.; Vijayaraghavan, R.; Tang, C.; Makarov, V.; Rappold, P.; Blum, K. A.; more...
    Genome Medicine (2022)

    Fulltext@MSK | Save
  • Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry
    Journal Article

    Nowatzke, J.; Guedeney, P.; Palaskas, N.; Lehmann, L.; Ederhy, S.; Zhu, H.; Cautela, J.; Francis, S.; Courand, P. Y.; Deswal, A.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Precision oncology: 2022 in review
    Review

    Rosen, E.; Drilon, A.; Chakravarty, D.
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Journal Article

    Lim, M.; Weller, M.; Idbaih, A.; Steinbach, J.; Finocchiaro, G.; Raval, R. R.; Ansstas, G.; Baehring, J.; Taylor, J. W.; Honnorat, J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Review

    Ged, Y.; Lee, C. H.
    Expert Review of Anticancer Therapy (2022)

    Fulltext@MSK | Save